The creation of Hepzero’s business plan marks an essential step in translating our scientific concept into a viable, real-world solution. While our laboratory work focuses on designing a dual-CRISPR, non-cutting repression system to silence HBV cccDNA, this document explores how such an innovation can be responsibly developed, funded, and distributed.
Our goal was to design a model where accessibility and sustainability are built into the foundation of biotechnology innovation. The plan details how Hepzero’s Access-First strategy enables equitable pricing across regions, ensuring that functional cure technologies do not remain limited to high-income countries. By combining scientific precision with financial realism, we aim to demonstrate that global health impact and commercial viability can reinforce one another rather than compete.
Through this business framework, Hepzero aligns with UN SDG Target 3.b — supporting the research, development, and equitable distribution of new medicines for diseases that disproportionately affect low- and middle-income populations. It is not only a roadmap for the company’s future, but also a reflection of our broader commitment: to make innovative biotechnology part of an inclusive and sustainable healthcare future.